BACKGROUND: We have previously shown that intragraft CD20+ B cells are associated with acute cellular rejection (ACR) and allograft loss. Phosphorylation of S6 ribosomal protein, a downstream target of the PI3K/Akt/mTOR pathway, promotes growth and proliferation of cells and could identify metabolically active cells such as alloantibody secreting plasma cells. Because CD20+ lymphocytes can differentiate into CD138+ plasma cells, we aimed to identify functionally active plasma cells by using intragraft CD138 quantification and p-S6RP staining and correlate these results with allograft rejection, function, and survival. METHODS: We examined 46 renal transplant biopsies from 32 pediatric patients who were biopsied for clinical suspicion of rejection. Immunohistochemical staining for C4d, CD20, CD138, and p-S6RP was performed. Patient creatinine clearance and graft status was followed up postbiopsy. RESULTS: Patients with greater than or equal to six CD138+ cells/high power field (hpf) had worse graft survival with a hazard ratio of 3.4 (95% CI 1.3-9.2) 2 years postbiopsy compared with those with 0 to 5 cells/hpf (P=0.016). CD138+ cells were stained for p-S6RP, indicating functionally active plasma cells. They were associated with ACR (P=0.004) and deteriorating graft function (R=0.22, P=0.001). Intragraft CD20+ and CD138+ cells found together in ACR were associated with poorer graft survival than either marker alone, hazard ratio 1.5 (95% CI 1.1-2.2, P=0.01). CONCLUSIONS: A threshold of greater than or equal to six CD138+ metabolically active plasma cells per hpf, coexisting with CD20+ B cells, was associated with poor allograft function and survival. This may represent an additional antibody-mediated process present in the setting of ACR and could play an important role in characterization and treatment of transplant rejection.
BACKGROUND: We have previously shown that intragraft CD20+ B cells are associated with acute cellular rejection (ACR) and allograft loss. Phosphorylation of S6 ribosomal protein, a downstream target of the PI3K/Akt/mTOR pathway, promotes growth and proliferation of cells and could identify metabolically active cells such as alloantibody secreting plasma cells. Because CD20+ lymphocytes can differentiate into CD138+ plasma cells, we aimed to identify functionally active plasma cells by using intragraft CD138 quantification and p-S6RP staining and correlate these results with allograft rejection, function, and survival. METHODS: We examined 46 renal transplant biopsies from 32 pediatric patients who were biopsied for clinical suspicion of rejection. Immunohistochemical staining for C4d, CD20, CD138, and p-S6RP was performed. Patientcreatinine clearance and graft status was followed up postbiopsy. RESULTS:Patients with greater than or equal to six CD138+ cells/high power field (hpf) had worse graft survival with a hazard ratio of 3.4 (95% CI 1.3-9.2) 2 years postbiopsy compared with those with 0 to 5 cells/hpf (P=0.016). CD138+ cells were stained for p-S6RP, indicating functionally active plasma cells. They were associated with ACR (P=0.004) and deteriorating graft function (R=0.22, P=0.001). Intragraft CD20+ and CD138+ cells found together in ACR were associated with poorer graft survival than either marker alone, hazard ratio 1.5 (95% CI 1.1-2.2, P=0.01). CONCLUSIONS: A threshold of greater than or equal to six CD138+ metabolically active plasma cells per hpf, coexisting with CD20+ B cells, was associated with poor allograft function and survival. This may represent an additional antibody-mediated process present in the setting of ACR and could play an important role in characterization and treatment of transplant rejection.
Authors: S M Meehan; P Domer; M Josephson; M Donoghue; A Sadhu; L T Ho; A J Aronson; J R Thistlethwaite; M Haas Journal: Hum Pathol Date: 2001-02 Impact factor: 3.466
Authors: Georg A Böhmig; Markus Exner; Antje Habicht; Martin Schillinger; Ursula Lang; Josef Kletzmayr; Marcus D Säemann; Walter H Hörl; Bruno Watschinger; Heinz Regele Journal: J Am Soc Nephrol Date: 2002-04 Impact factor: 10.121
Authors: Shamila Mauiyyedi; Marta Crespo; A Bernard Collins; Eveline E Schneeberger; Manuel A Pascual; Susan L Saidman; Nina E Tolkoff-Rubin; Winfred W Williams; Francis L Delmonico; A Benedict Cosimi; Robert B Colvin Journal: J Am Soc Nephrol Date: 2002-03 Impact factor: 10.121
Authors: Minnie Sarwal; Mei-Sze Chua; Neeraja Kambham; Szu-Chuan Hsieh; Thomas Satterwhite; Marilyn Masek; Oscar Salvatierra Journal: N Engl J Med Date: 2003-07-10 Impact factor: 91.245
Authors: Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: C Lefaucheur; D Nochy; J Andrade; J Verine; C Gautreau; D Charron; G S Hill; D Glotz; C Suberbielle-Boissel Journal: Am J Transplant Date: 2009-05 Impact factor: 8.086
Authors: Helen P Pizzo; Robert B Ettenger; David W Gjertson; Elaine F Reed; Jennifer Zhang; H Albin Gritsch; Eileen W Tsai Journal: Pediatr Nephrol Date: 2016-06-10 Impact factor: 3.714
Authors: Davy Vanhoutte; Geert C van Almen; Lucas N L Van Aelst; Johan Van Cleemput; Walter Droogné; Yu Jin; Frans Van de Werf; Peter Carmeliet; Johan Vanhaecke; Anna-Pia Papageorgiou; Stephane Heymans Journal: Eur Heart J Date: 2012-11-08 Impact factor: 29.983